Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) – Drugs In Development, 2024 report and make more profitable business decisions.
Mucopolysaccharidosis type I (MPS I) is an inherited lysosomal storage disorder caused by a deficiency of alpha-L-iduronidase, a lysosomal enzyme normally required for the breakdown of certain complex carbohydrates known as glycosaminoglycans (GAGs). Symptoms include abnormal bones in the spine, claw hand, cloudy corneas, deafness, and heart valve problems. Treatment includes bone marrow transplantation, enzyme therapy, and gene therapy.
The Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) drugs in development market research report provide comprehensive information on the therapeutics under development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 24 molecules, with 21 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
ArmaGen IncBioStrategies LC
Chengdu Genevector Biotechnology Co Ltd
Cinnagen Co
Denali Therapeutics Inc
EdiGene Inc
Eloxx Pharmaceuticals Inc
Gain Therapeutics Inc
Immusoft Corp
JCR Pharmaceuticals Co Ltd
Jupiter Neurosciences Inc
Mina Therapeutics Ltd
Neurogt Inc
Orchard Therapeutics Plc
Ossianix Inc
Paradigm Biopharmaceuticals Ltd
RegenxBio Inc
ReqMed Co Ltd
Sigilon Therapeutics Inc
Simon Fraser University
Tega Therapeutics Inc
University of Alabama
University of Pennsylvania
Table of Contents
Table
Figures
Frequently asked questions